Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

Francisco Robert,Ecaterina Elena Dumbrava,Yan Xing,Elizabeth Mills,James L. Freddo,Charles P. Theuer,Bonne J. Adams,James Lawrence,Alicia A Trigeiro,Claire Xu,Yuan Meng,Linda Lee,Yonggang Zhao,Jerry Wang,Huaqiong Joan Shen,Michael Gordon

Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

2021

Francisco Robert
Ecaterina Elena Dumbrava
Yan Xing
Elizabeth Mills
James L. Freddo
Charles P. Theuer
Bonne J. Adams
James Lawrence
Alicia A Trigeiro
Claire Xu
Yuan Meng
Linda Lee
Yonggang Zhao
Jerry Wang
Huaqiong Joan Shen
Michael Gordon

2511Background: CD73 is implicated in tumor resistance to checkpoint immunotherapy (CPI) and plays a critical role in adenosine-mediated immune suppression. Uliledlimab, a differentiated CD73 antib...

Keywords:

Internal medicine
Medicine
clinical efficacy
in patient
Oncology
Pharmacokinetics
Immunotherapy
Atezolizumab
Immune system
Antibody
Pharmacodynamics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations